Recent Updates
Recently added Catalysts
CNSY Positive Sentiment

Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform

Thursday, August 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Cerenome has chosen XiFin Empower RCM to manage revenue cycle and clearinghouse services for its CNSide platform. This strategic move aims to accommodate the anticipated billing volumes as the CNSide assay is scheduled to start billing in Q3 2026. The company is preparing for a backlog of tests and concurrent case billing.
Price reaction · baseline $3.91 (2026-08-05 close) · hit pre-market · clean, no other CNSY news in the window
day 0 close
-1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Cerenome has selected XiFin Empower RCM for efficient revenue cycle management.
  • The CNSide platform is expected to support high billing volumes.
  • Billing for CNSide assays is set to begin in Q3 2026, indicating growth.

Full Press Release Details

Scalable revenue cycle ecosystem designed to support anticipated billing volumes; CNSide assay billing to begin in Q3 2026 with accumulated 2026 backlog of tests and concurrent case billing HOUSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome,

Frequently Asked Questions

What is the purpose of XiFin Empower RCM?

XiFin Empower RCM is selected for managing revenue cycle and clearinghouse services.

When will CNSide assay billing begin?

CNSide assay billing is expected to start in Q3 2026.

What does the CNSide platform support?

The CNSide platform is designed to support anticipated high billing volumes.

Who is the parent company of CNSide Diagnostics?

CNSide Diagnostics is a wholly-owned subsidiary of Cerenome.

ShareAdd on Google
Tags: CNSY Viatris Investor Conferences Healthcare Cerenome CNSide XiFin revenue cycle management billing
Last updated: Aug 6, 2026

Biotech snapshot

Cash runway
$9M liquidity · $3M/mo burn
~3 mo
High dilution risk